A Phase IIb, Randomized, Placebo-Controlled, Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-936557 in Subjects with Active Ulcerative Colitis (UC)

Grants and Contracts Details

StatusFinished
Effective start/end date8/15/116/1/17

Funding

  • Bristol Myers Squibb Company: $109,379.00